Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | BLM | P54132 | 1/20 | 0.42 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.42 |
| ▸ | PDE4A | P27815 | 1/20 | 0.41 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.36 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.36 |
| ▸ | AHR | P35869 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | GAA | P10253 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL32675859 | 1.00 | LMNA (0.42) | LMNAHSD17B10CYP1A2THRBBLM | |
| Methylamine SCHEMBL17309971 | 0.96 | PDE4A (0.40) | LMNAHSD17B10CYP1A2THRBBLM | |
| Formaldehyde SCHEMBL6476807 | 0.94 | POLB (0.40) | LMNAHSD17B10CYP1A2THRBBLM | |
| Altretamine SCHEMBL1978783 | 0.91 | LMNA (0.48) | LMNAHSD17B10CYP1A2THRBBLM | |
| Acetic Acid SCHEMBL28195268 | 0.89 | POLB (0.49) | LMNAHSD17B10CYP1A2THRBBLM | |
| SCHEMBL19144867 | 0.88 | CA1 (0.40) | LMNAHSD17B10CYP1A2THRBBLM | |
| SCHEMBL1033226 | 0.84 | CYP1A2 (0.53) | LMNAHSD17B10CYP1A2THRBBLM | |
| Pentamethyl Melamine SCHEMBL38832 | 0.84 | LMNA (0.61) | LMNAHSD17B10CYP1A2THRBBLM | |
| Altretamine SCHEMBL4448907 | 0.84 | LMNA (0.61) | LMNAHSD17B10CYP1A2THRBBLM | |
| Pentamethyl Melamine SCHEMBL15346326 | 0.81 | LMNA (0.58) | LMNAHSD17B10CYP1A2THRBBLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1889 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12364682-B2 | Use of tegaserod in preparation of anti-tumor drug | QINGDAO HAIJI BIOMEDICINE CO., LTD. (CN) | 2025-07-22 | — | — | US | claimed |
| US-20250059301-A1 | Fusion Protein Construct | NORTHWESTERN UNIVERSITY | 2025-02-20 | — | — | US | claimed |
| CN-119463251-A | PVA/PEO/PU composite water-soluble patterned film and preparation method and application thereof | 孙琇芳 | 2025-02-18 | — | — | CN | claimed |
| US-20240316079-A1 | USE OF AKR1C3-ACTIVATED COMPOUND | OBI PHARMA, INC. (CN) | 2024-09-26 | — | — | US | claimed |
| CN-118105513-A | Conjugates comprising self-degrading groups and methods related thereto | 乐高化学生物科学股份有限公司 | 2024-05-31 | — | — | CN | claimed |
| CN-118046691-A | Acrylic acid type water-soluble pattern film, preparation method and application thereof | 孙琇芳 | 2024-05-17 | — | — | CN | claimed |
| EP-4297872-A1 | USE OF AKR1C3-ACTIVATED COMPOUND | OBI Pharma, Inc. (TW) | 2024-01-03 | — | — | EP | claimed |
| CN-117244076-A | Conjugates comprising self-degrading groups and methods related thereto | 乐高化学生物科学股份有限公司 | 2023-12-19 | — | — | CN | claimed |
| CN-116999571-A | Antibody-drug conjugates comprising anti-B7-H3 antibodies | 尹图赛利有限公司 | 2023-11-07 | — | — | CN | claimed |
| CN-113929930-B | Temperature-responsive persulfate slow-release gel and preparation method and application thereof | 中国环境科学研究院 | 2023-08-11 | — | — | CN | claimed |
| US-20040023961-A1 | Aryl ureas with raf kinase and angiogenisis inhibiting activity | BAYER CORPORATION | 2004-02-05 | — | — | US | claimed |
| US-20030216396-A1 | Pyridine, quinoline, and isoquinoline N-oxides as kinase inhibitors | BAYER CORPORATION | 2003-11-20 | — | — | US | claimed |
| US-20030216446-A1 | Aryl ureas as kinase inhibitors | BAYER CORPORATION (US) | 2003-11-20 | — | — | US | claimed |
| WO-2003068223-A1 | ARYL UREAS WITH RAF KINASE AND ANGIOGENESIS INHIBITING ACTIVITY | BAYER CORPORATION (US) | 2003-08-21 | — | — | WO | claimed |
| WO-2003068746-A1 | ARYL UREAS AS KINASE INHIBITORS | BAYER PHARMACEUTICALS CORPORATION (US) | 2003-08-21 | — | — | WO | claimed |
| WO-2003055890-A1 | THIENOPYRIMIDINE DERIVATIVE COMPOUNDS AS INHIBITORS OF PROLYLPEPTIDASE, INDUCERS OF APOPTOSIS AND CANCER TREATMENT AGENTS | BAYER PHARMACEUTICALS CORPORATION (US) | 2003-07-10 | — | — | WO | claimed |
| WO-2003055489-A1 | 2,4-DIAMINO-PYRIMIDINE DERIVATIVE COMPOUNDS AS INHIBITORS OF PROLYLPEPTIDASE, INDUCERS OF APOPTOSIS AND CANCER TREATMENT AGENTS | BAYER PHARMACEUTICALS CORPORATION (US) | 2003-07-10 | — | — | WO | claimed |
| WO-2003055866-A1 | QUINAZOLINE AND QUINOLINE DERIVATIVE COMPOUNDS AS INHIBITORS OF PROLYLPEPTIDASE, INDUCERS OF APOPTOSIS AND CANCER TREATMENT AGENTS | BAYER PHARMACEUTICALS CORPORATION (US) | 2003-07-10 | — | — | WO | claimed |
| WO-2003040141-A1 | OXAZOLYL-PHENYL-2,4-DIAMINO-PYRIMIDINE COMPOUNDS AND METHODS FOR TREATING HYPERPROLIFERATIVE DISORDERS | BAYER PHARMACEUTICALS CORPORATION (US) | 2003-05-15 | — | — | WO | claimed |
| US-5534625-A | 2,4,6-TRIAMINO-1,3,5-TRIAZINE DERIVATIVES; OVARIES | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 1996-07-09 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12364682-B2 | Use of tegaserod in preparation of anti-tumor drug | STAT3, JAK2, JAK1 | LMNA 4823/4885HSD17B10 4096/4885CYP1A2 4546/4885 |
| US-20240316079-A1 | USE OF AKR1C3-ACTIVATED COMPOUND | AKR1A1, AKR1C1, AK1 | LMNA 3534/4885HSD17B10 134/4885CYP1A2 641/4885 |
| US-20250059301-A1 | Fusion Protein Construct | RPS27A, CD2BP2, JMJD7 | LMNA 4363/4885HSD17B10 2317/4885CYP1A2 2913/4885 |
| US-20030216396-A1 | Pyridine, quinoline, and isoquinoline N-oxides as kinase inhibitors | MAP2K2, MAP2K7, MAPK1 | LMNA 4406/4885HSD17B10 4542/4885CYP1A2 481/4885 |
| US-20030216446-A1 | Aryl ureas as kinase inhibitors | MAPK1, MAP3K1, MAP3K6 | LMNA 4377/4885HSD17B10 4000/4885CYP1A2 894/4885 |
| US-20040023961-A1 | Aryl ureas with raf kinase and angiogenisis inhibiting activity | BRAF, FLT1, RAF1 | LMNA 4417/4885HSD17B10 4286/4885CYP1A2 2073/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.